共 50 条
- [31] The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 studyCANCER BIOLOGY & MEDICINE, 2021, 18 (03) : 841 - 848Zhang, WeiSu, LipingLiu, LihongGao, YuhuanWang, QuanshunSu, HangSong, YuhuanZhang, HuilaiShen, JingJing, HongmeiWang, ShuyeCen, XinanLiu, HuiLiu, AichunLi, ZengjunLuo, JianminHe, JianxiaWang, JingwenO'Connor, O. A.Zhou, Daobin
- [32] The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 studyCancer Biology & Medicine , 2021, (03) : 841 - 848Wei ZhangLiping SuLihong LiuYuhuan GaoQuanshun WangHang SuYuhuan SongHuilai ZhangJing ShenHongmei JingShuye WangXinan CenHui LiuAichun LiuZengjun LiJianmin LuoJianxia HeJingwen WangO.A.O'ConnorDaobin Zhou
- [33] Evaluation of Idelalisib with B-Cell Receptor or Orthogonal Pathway Inhibitors in Diffuse Large B-Cell Lymphoma Cell Lines in Vitro and In VivoBLOOD, 2016, 128 (22)Meadows, SarahYahiaoui, AnellaSorensen, RickCui, Zhi-HuaBrockett, RobertKeegan, Kathleen S.Tannheimer, Stacey
- [34] A Phase 1 Study With the Novel B-Cell Lymphoma 2 Inhibitor BGB-11417 as Monotherapy or in Combination With Zanubrutinib in Patients With B-Cell Malignancies: Preliminary DataCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S267 - S268Soumerai, Jacob D.Opat, StephenCheah, Chan Y.Lasica, MasaVerner, EmmaBrowett, Peter J.Chan, HenryBarca, Eva GonzalezHilger, JamesFang, YiqianSimpson, DavidTam, Constantine S.
- [35] Pembrolizumab in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell LymphomaBLOOD, 2018, 132Smith, Stephen D.Lynch, Ryan C.Till, Brian G.Cowan, Andrew J.Wu, Qian V.Voutsinas, Jenna M.Shadman, MazyarBlue, KatieShustov, Andrei R.Kanan, SandraLow, LaurenCassaday, Ryan D.Fromm, Jonathan R.Gopal, Ajay K.
- [36] Phase 1b Trial of Cereblon-Modulating Agents Iberdomide and CC-99282 Plus R-CHOP in Previously Untreated Aggressive B-Cell LymphomaBLOOD, 2022, 140 : 9475 - 9477Westin, JasonMartin Garcia-Sancho, AlejandroHoffmann, MarcVassilakopoulos, Theodoros P.Yeh, Su-PengGkasiamis, ArgyriosPatah, PolianaPatel, ArpankumarLi, JuNowakowski, Grzegorz S.
- [37] A Phase 1b/2 Study of Chidamide Combined with CHOP in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL)BLOOD, 2019, 134Shi, YuankaiGui, LinCao, JunningZhang, HuilaiZhu, JunJi, DongmeiFan, QianSong, YuqinShen, WeinaBai, GuiyingHan, Ming-ZheJiang, Shiyu
- [38] Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular AnalysisBLOOD, 2019, 134Melani, ChristopherLakhotia, RahulPittaluga, StefaniaMiljkovic, Milos D.Muppidi, Jagan R.Portell, Craig A.Farah, RaficLee, Seung TaeJuanitez, Anna MarieChou, Lydia L.Steinberg, Seth M.Jaffe, Elaine S.Staudt, LouisRoschewski, MarkWilson, Wyndham
- [39] A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in CombinationWith Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (05): : 309 - +Ribrag, VincentLee, Seung TaeRizzieri, DavidDyer, Martin J. S.Fayad, LuisKurzrock, RazelleAndritsos, LeslieBouabdallah, RedaHayat, AmjadBacon, LarryJiang, YuMiah, KowserDelafont, BrunoHamid, OdayAnyanwu, StephanieMartinez, PabloHess, Brian
- [40] y Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients with Relapsed/ Refractory Diffuse Large B-Cell LymphomaBLOOD, 2019, 134Jaeger, UlrichWorel, NinaMcGuirk, Joseph P.Riedell, Peter A.Fleury, IsabelleBorchmann, PeterChu, JufenAbdelhady, Ahmed M.Forcina, AlessandraPacaud, Lida BubuteishviliWaller, Edmund K.